GlassScriptPhysician profile
Alfa Lafleur
NPI 1992286272
$10,078.64
in general payments reported to CMS, 2019-2025
66 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,940 · 2022: $2,599 · 2023: $4,014 · 2024: $1,050 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,294 · Consulting Fee: $1,135 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,293.71 |
| Consulting Fee | $1,135.00 |
| Education | $110.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,059.63 | 2021-2025 | Jakafi, Monjuvi, Jakafi |
| Taiho Oncology, INC. | $974.60 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $793.61 | 2021-2025 | Datroway, Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $570.06 | 2022-2024 | |
| Daiichi Sankyo INC. | $529.45 | 2021-2023 | Enhertu |
| Pfizer INC. | $441.71 | 2022-2025 | |
| Janssen Biotech, INC. | $379.99 | 2021-2024 | Imbruvica, Darzalex, Erleada |
| Merck Sharp & Dohme LLC | $353.02 | 2022-2024 | Keytruda, Lynparza |
| Genzyme Corporation | $319.69 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $313.27 | 2021-2023 | Zepzelca |
| E.R. Squibb & Sons, L.L.C. | $284.88 | 2021-2024 | Opdualag, Opdivo, Augtyro |
| Gilead Sciences, INC. | $279.49 | 2021-2024 | Trodelvy |
| Seagen INC. | $253.72 | 2021-2023 | Tivdak, Adcetris |
| Lilly USA, LLC | $251.96 | 2021-2024 | Verzenio, Retevmo, Jaypirca |
| Puma Biotechnology, INC. | $224.52 | 2021-2023 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfa Lafleur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.